-
公开(公告)号:US20240042713A1
公开(公告)日:2024-02-08
申请号:US18273145
申请日:2022-12-06
Applicant: OCULAR THERAPEUTIX, INC.
Inventor: Peter JARRETT , Rami EL-HAYEK , Erica KAHN , Dinesh HASWANI , Eric DICKINSON , Timothy S. JARRETT , Michael MCGRATH
IPC: B29D11/00 , A61K31/573 , A61K9/00
CPC classification number: B29D11/0074 , A61K31/573 , A61K9/0051 , B29K2071/02
Abstract: The present invention is directed to a method of preparing a sustained release biodegradable ocular insert or implant comprising melt extruding or injection molding a polymer composition and an active agent to form an insert or implant suitable for administration to the body. e.g., ocular administration. The method comprises feeding the polymer composition and the active into an extruder; mixing the components in the extruder; extruding a strand; and cutting the strand into unit dose inserts or implants.
-
公开(公告)号:US20250064760A1
公开(公告)日:2025-02-27
申请号:US18726302
申请日:2023-01-06
Applicant: OCULAR THERAPEUTIX, INC.
Inventor: Charles D. BLIZZARD , Ankita DESAI , Rami EL-HAYEK , Michael GOLDSTEIN , Peter JARRETT , Oktay UZUN
IPC: A61K31/165 , A61K9/00
Abstract: In certain embodiments, the invention relates to a sustained release biodegradable intracanalicular insert containing nepafenac dispersed in a hydrogel for the treatment of pain and inflammation. According to certain embodiments of the present invention, pain and inflammation is treated by administering a biodegradable insert into the superior and/or inferior canaliculus of the eye, wherein the insert provides sustained release of a nonsteroidal anti-inflammatory such as nepafenac that is effective for treating pain and inflammation in a patient, e.g., during a period of one or more weeks, with only a single administration, and without the need for removal of the drug-depleted insert.
-
公开(公告)号:US20230390189A1
公开(公告)日:2023-12-07
申请号:US18033689
申请日:2021-10-26
Applicant: OCULAR THERAPEUTIX, INC.
Inventor: Charles D. BLIZZARD , Arthur DRISCOLL , Rami EL-HAYEK , Michael GOLDSTEIN , Joseph IACONA , Peter JARRETT , Timothy S. JARRETT , Erica KAHN , Zachary LATTRELL
IPC: A61K9/00 , A61K45/06 , A61P27/02 , A61K31/4439
CPC classification number: A61K9/0051 , A61K45/06 , A61P27/02 , A61K31/4439
Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
-
4.
公开(公告)号:US20230338281A1
公开(公告)日:2023-10-26
申请号:US18020544
申请日:2021-09-23
Applicant: OCULAR THERAPEUTIX, INC.
Inventor: Charles D. BLIZZARD , Rami EL-HAYEK , Michael GOLDSTEIN , Peter JARRETT , Andrew VANSLETTE
CPC classification number: A61K9/0051 , A61K9/06 , A61K49/0039 , A61K49/0056 , A61K38/13 , A61P27/02
Abstract: Provided herein are sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
-
公开(公告)号:US20250092013A1
公开(公告)日:2025-03-20
申请号:US18706306
申请日:2022-10-14
Applicant: OCULAR THERAPEUTIX, INC.
Inventor: Peter JARRETT , Rami EL-HAYEK
IPC: C07D401/06 , A61K31/4439
Abstract: In certain embodiments, the invention is directed to a compound of formula I: wherein: X1 is selected from N or N+Y1; X2 is selected from NH or NY2; X3 is selected from NH or NY3; Y is selected from —CH2OCO(OCH2CH2)n1OM1; or —CH2OCO(CH2)n1aCOOH; Y2 is selected from —CH2OCO(OCH2CH2)n2OM2; or —CH2OCO(CH2)n2aCOOH; Y3 is selected from —CH2OCO(OCH2CH2)n3OM3; or —CH2OCO(CH2)n3aCOOH; n1, n1a n2a, n3 and n3a are independently 0 or an integer from 1 to 8; M1, M2 and M3 are independently selected from H, optionally substituted C1-6alkyl and optionally substituted aryl wherein at least one of X1, X2 and X3 is not N or NH; and pharmaceutically acceptable salts thereof.
-
公开(公告)号:US20240041647A1
公开(公告)日:2024-02-08
申请号:US18282124
申请日:2022-03-24
Applicant: OCULAR THERAPEUTIX, INC.
Inventor: Peter JARRETT , Erik WONG , Eric DICKINSON
IPC: A61F9/00
CPC classification number: A61F9/0017
Abstract: A system (100) includes a first assembly (110A) and a second assembly (110B). The first assembly (110A) includes a body (120) forming a first interior volume, a plunger (130) comprising a first distal end disposed within the first interior volume, a wire comprising a first distal end secured to the first distal end of the plunger (130), and a plunger clip (140) configured to interface with the plunger (130) and the body (120) to prevent actuation of the plunger (130). The second assembly (110B) includes a cowl (150) forming a second interior volume, a needle comprising a hub and a shaft, and a cowl cap disposed partially within the hub to secure the implant in the shaft. A first distal end of the shaft is connected to the hub. The hub is disposed within the second interior volume. The shaft is configured to receive an implant.
-
公开(公告)号:US20240390183A1
公开(公告)日:2024-11-28
申请号:US18619321
申请日:2024-03-28
Applicant: OCULAR THERAPEUTIX, INC.
Inventor: Peter JARRETT , Erik WONG
IPC: A61F9/00
Abstract: Disclosed in certain embodiments is an intracanalicular injectable applicator device includes a body forming a cavity and a cannula coupled to a first distal end of the body. The cannula forms a channel that is aligned with the cavity of the body. The cannula is configured to store an intracanalicular injectable in the channel. The intracanalicular injectable applicator device further includes a tip structure coupled to the body. The tip structure is disposed around at least a portion of the cannula. A distal end of the tip structure is configured to dilate a lacrimal punctum by inserting the distal end of the tip structure into the canaliculus via the lacrimal punctum. The intracanalicular injectable applicator device further includes an actuating structure configured to push the intracanalicular injectable through the channel and the distal end of the tip structure into a canaliculus via a lacrimal punctum.
-
公开(公告)号:US20240082054A1
公开(公告)日:2024-03-14
申请号:US18278538
申请日:2022-02-23
Applicant: OCULAR THERAPEUTIX, INC.
Inventor: Peter JARRETT , Erik WONG
IPC: A61F9/00
CPC classification number: A61F9/0017
Abstract: Disclosed in certain embodiments is an intracanalicular injectable applicator device includes a body forming a cavity and a cannula coupled to a first distal end of the body. The cannula forms a channel that is aligned with the cavity of the body. The cannula is configured to store an intracanalicular injectable in the channel. The intracanalicular injectable applicator device further includes a tip structure coupled to the body. The tip structure is disposed around at least a portion of the cannula. A distal end of the tip structure is configured to dilate a lacrimal punctum by inserting the distal end of the tip structure into the canaliculus via the lacrimal punctum. The intracanalicular injectable applicator device further includes an actuating structure configured to push the intracanalicular injectable through the channel and the distal end of the tip structure into a canaliculus via a lacrimal punctum.
-
公开(公告)号:US20230285282A1
公开(公告)日:2023-09-14
申请号:US18121256
申请日:2023-03-14
Applicant: OCULAR THERAPEUTIX, INC.
Inventor: Charles D. BLIZZARD , Arthur DRISCOLL , Rami EL-HAYEK , Michael GOLDSTEIN , Joseph IACONA , Peter JARRETT , Timothy S. JARRETT , Erica KAHN , Zachary LATTRELL
IPC: A61K9/00 , A61K31/4439 , A61K47/34 , A61K31/402 , A61K38/13 , A61K31/436 , A61K31/155 , A61K31/4745 , A61K31/664 , A61K31/365 , A61K31/675 , A61K31/519 , A61K31/52 , A61K31/5377 , A61K38/21 , C07K16/24 , A61K31/16 , A61K31/454 , A61K38/03 , A61K31/421 , A61K31/475 , A61K31/7068 , C07K16/28 , A61K31/7088 , A61K31/573 , A61K31/58 , A61K31/569 , A61K31/575
CPC classification number: A61K9/0051 , A61K31/4439 , A61K47/34 , A61K31/402 , A61K38/13 , A61K31/436 , A61K31/155 , A61K31/4745 , A61K31/664 , A61K31/365 , A61K31/675 , A61K31/519 , A61K31/52 , A61K31/5377 , A61K38/21 , C07K16/241 , A61K31/16 , A61K31/454 , A61K38/03 , A61K31/421 , A61K31/475 , A61K31/7068 , C07K16/2896 , A61K31/7088 , A61K31/573 , A61K31/58 , A61K31/569 , A61K31/575 , C07K2319/00 , C07K2317/24
Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
-
-
-
-
-
-
-
-